Search

BACKGROUND: Regardless of GBM patient prognosis remains dire, there is a patient group, in which profit from current diagnostic methods and treatment strategies progress has yielded extension of both OS and PFS, that again recall question of recurrent GBM solution.Our work is aimed at result evaluation of our treatment strategy for the most malignant subtype of GBM - IDH wild type. MATERIAL AND METHODS: 116 consecutive patients with GBM IDH wild-type were enrolled. Recurrent GBM was defined as increasing more than 20–30% of previous, residual tumour volume, or tumour regrowing after radiologically radical surgery. We consider as a best solution repeated surgery following oncotherapy. In case unsuitable for redo-surgery, we accepted oncotherapy rechallenge. CRITERIA FOR REDO-SURGERY: Time of recurrency evolving ≥ 6 months after surgery, Clinical condition - Karnofsky score (KS) ≥ 70% and Performance status (PS) WHO ≤ gr. 2, Local recurrency, without multilocality, Option for considerable tumor volume reduction, minimally ≤ 70%; tumour location; CRITERIA FOR REPEATED ONCOTHERAPY: Time of recurrency evolving ≥ 6 motnts after prime surgery, Clinical condition - Karnofsky score (KS) ≥ 70% and Performance status (PS) WHO ≤ gr. 2, Local recurrency, without multilocality, No option for considerable tumour volume reduction, minimally ≤ 70%; tumour location. RESULTS: 23 patients met these criteria. Such treatment selection drew improvement of both PFS (10,5 months; 8.94,17.91)) and OS (19,2 months; (15.28,30.82)). A good clinical condition, longer time to the tumour recurrency commitment, primary radical surgery, following Stupp protocol a radical redo-surgery, following chemotherapy were positive clinical prognostic factors. Solely rechallenge oncotherapy (reradiation, chemotherapy/temozolomid) had lesser positive impact. Regarding cytogenetic tumour profile, based on FISH, increasing copy number P53 and CCND1 were approved as a positive prognostic factor. CONCLUSION: GBMs IDH wild-type are the most malignant subset, but these patients have relatively heterogenous life expectancy. Thera are missed relevant prognostic factors and our work attempted to change it. As emerged from this analysis, OS and PFS predominantly rely on genetic features (P53, CCND1) of certain tumour. The most important issue for successful recurrent GBM treatment was set up appropriate indication criteria. When we evaluated our patient group, the patients, who un-fulfilled criteria, underwent redo-surgery, predominantly for the patient′s and family urges.